

**REMARKS**


The specification has been amended to provide a cross-reference to the previously filed International Application. The claims have also been amended to delete improper multiple dependencies and to place the application into better form for examination. Entry of the present amendment and favorable action on the above-identified application are earnestly solicited.

Attached hereto is a marked-up copy of the changes made to the application by this Amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
\_\_\_\_\_  
Marc S. Weiner, #32,181

MSW/cgc  
0020-4867P

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

Attachment: Version With Markings Showing Changes Made

(Rev. 01/22/01)

Docket No. 0020-4867P

**VERSION WITH MARKINGS SHOWING CHANGES MADE**

The specification has been amended to provide cross-referencing to the International Application.

The claims have been amended as follows:

4. (Amended) The peptide fragment or a series of peptide fragments of [any one of claims 1 to 3]claim 1, wherein said peptide fragment or fragments (a) are recovered in fractions of molecular weight 10 kDa to 30 kDa by molecular size fractionation with membrane; (b) have structures showing isoelectric points at between pH 7 and pH 8 and at pH 8 or more in blood as a result of testing of binding to ion exchange resin; (c) show two bands at molecular weight 13 to 14 kDa and two bands at 16 to 17 kDa, the latter being a glycosylated form of the former, in non-reductive SDS-PAGE; and (d) have a band patten of 3 to 4 kDa, 7 to 9 kDa and 10 to 12 kDa in SDS-PAGE under reductive condition in addition to the bands (c).

5. (Amended) The peptide fragment or a series of peptide fragments of [any one of claims 1 to 4]claim 1, wherein said peptide fragment or fragments correspond to the bands at 3 to 4 kDa, 7 to 9 kDa and 10 to 12 kDa in SDS-PAGE under reductive condition.

6. (Amended) A medicament for protecting from exacerbation of conditions of, preventing or treating diseases related to cell death, comprising as an active ingredient the peptide fragment or a series of peptide fragments having the cell death-inhibitory activity of [any one of claims 1 to 5]claim 1.

8. (Amended) A medicament for protecting from exacerbation of conditions of, preventing or treating diseases related to oxidation/reduction reaction, comprising as an active ingredient the peptide fragment or a series of peptide fragments having the cell death-inhibitory activity of [any one of claims 1 to 5]claim 1.

9. (Amended) A medicament for protecting from exacerbation of conditions of, preventing or treating diseases in which cells of the immune system are involved, comprising as an active ingredient the peptide fragment or a series of peptide fragments having the cell death-inhibitory activity of [any one of claims 1 to 5]claim 1.

10. (Amended) An additive for cell culture comprising as an active ingredient the peptide fragment or a series of peptide fragments having the cell death-inhibitory activity of [any one of claims 1 to 5]claim 1.

[illegible]